Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy
- Citation:
- Clin Cancer Res vol 27 (11) 3116-25
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- Parents:
- 3244
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, BCRF , R01-CA229409
- Corr. Author:
- Tomás Pascual
- Authors:
- Tomás Pascual Aranzazu Fernandez-Martinez Maki Tanioka M. Vittoria Dieci Sonia Pernas Joaquin Gavila Valentina Guarnieri Javier Cortes Patricia Villagrasa Núria Chic Maria Vidal Barbara Adamo Montserrat Muñoz Gaia Griguolo Antonio Llombart Pierfranco Conte Mafalda Oliveira Benedetta Conte Laia Paré Patricia Galvan Lisa A. Carey Charles M. Perou Aleix Prat
- Networks:
- Study
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-40601
- Phases:
- 3
- Keywords:
- intrinsic subtype, HER2-positive, Chemo-Endocrine Score, PAM50, breast cancer, gene expression